foxo4-dri human clinical trial peptide senolytic Molecular modelling of the FOXO4-TP53 interaction to design senolytic FOXO4-DRI Peptide - Nationwide Peptides
Description
Targeted tissue repair for gut lining, tendons, ligaments, and soft tissue injuries
worked with daily injections of 50 mg (which are extremely high doses)
The dose tiers are wider apart in absolute milligrams, the optional intermediate steps add flexibility that semaglutide does not offer, and the maximum dose of 15 mg reflects the dual-receptor mechanism that requires higher absolute amounts to achieve full therapeutic effect
But these aren't approved medical uses
However, much remains to be understood about biomarkers and how they can best be used for diagnosis
Our conversation has been edited and condensed
